Compare NAAS & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAAS | BGLC |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | China | Malaysia |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 10.1M |
| IPO Year | 2017 | N/A |
| Metric | NAAS | BGLC |
|---|---|---|
| Price | $3.50 | $4.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.6K | ★ 311.3K |
| Earning Date | 03-31-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,817,052.00 | $9,465,006.00 |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.21 |
| 52 Week Low | $1.96 | $2.01 |
| 52 Week High | $40.32 | $15.60 |
| Indicator | NAAS | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 41.85 |
| Support Level | $3.31 | $4.00 |
| Resistance Level | $3.89 | $4.31 |
| Average True Range (ATR) | 0.26 | 0.26 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 49.82 | 33.47 |
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.